Tofacitinib
![1 PHAR 827: Th1/Th17 Mediated Diseases [Psoriasis] (Leo R](http://data.docslib.org/img/264x/31c08de57da010df96c01288067664de.webp)
Top View
- 15. COVID-19 Tedavisinde IL-1, IL-6 Ve TNF-Α Anti-Sitokin Monoklonal Antikor Kullanımı Prof
- Real-World Comparative Effectiveness and Safety of Tofacitinib And
- E001214.Full.Pdf
- Standards, Perspektiven Und Grenzen Der Konservativen Therapie
- Stembook 2018.Pdf
- Benlysta® (Belimumab) Prior Authorization With
- Safety of Tofacitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) - Cardiovascular Endpoints
- Recent Biotherapies and Infections
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- Cimzia (Certolizumab Pegol) C10269-A
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Dissecting the Heterogeneity in T-Cell Mediated Inflammation In
- New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases
- RMD Commentary, JAK Kinase Inhibitors: a Preferred Alternative to TNF Inhibitors?
- Tofacitinib Citrate PATIENT FACT SHEET (Xeljanz and Xeljanz XR)
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases Or Other Immune-Mediated Diseases: a Systematic Review and Meta-Analysis Pablo A
- Coccidioidomycosis
- XELJANZ® Safety Review Recommendation Issued in the European Union